-- 根據德國聯邦統計局週三公佈的初步數據，德國4月年通膨率從3月的2.7%上升到2.9%。 最新數據顯示，通膨率低於市場普遍預期的3%。 4月消費者物價指數季增0.6%，低於前值1.1%及市場預期的0.7%。 4月調和通膨率為2.9%，低於前值2.8%和市場預期的3.1%。同時，4月調和消費者物價指數月增0.5%，低於前值1.2%和市場預期的0.8%。
Related Articles
Australia
Ryde Signs MoU With VinaTaxi to Explore Vietnam Opportunities
Ryde Group (RYDE) said Wednesday that it has signed a memorandum of understanding with VinaTaxi to explore strategic collaboration opportunities in Vietnam.The areas of exploration include the deployment of Ryde's platform within VinaTaxi's taxi fleet, and the development of an electric motorcycle ride-hailing ecosystem, the company said.Price: $1.20, Change: $+0.02, Percent Change: +1.61%
$RYDE
Research
Research Alert: Biogen Q1 Earnings: Strong Beat Overshadowed By Lowered Full-year Eps Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Biogen delivered strong Q1 2026 results with non-GAAP EPS of $3.57 (+18% Y/Y) significantly exceeding the consensus of $2.95, while revenue of $2.478B (+2% Y/Y) beat expectations of $2.2B. Growth products sustained impressive momentum, generating $851M (+12% Y/Y), now representing one-third of total revenue, with LEQEMBI collaboration revenue up 80% Y/Y to $60M and the MS franchise showing better-than-expected resilience at $779M (-4% Y/Y). We view the continued acceleration of growth products as demonstrating successful portfolio diversification away from MS dependence. Management downgraded 2026 non-GAAP EPS guidance to $14.25-$15.25 from $15.25-$16.25, primarily reflecting acquired IPR&D charges. The proposed $5.6B Apellis acquisition, expected to close in Q2 2026, will add SYFOVRE and EMPAVELI to the growth portfolio and is anticipated to be accretive in 2027, in our view. We expect the combined revenue from these assets to grow in the mid-to-high teens for at least the next two years.
$BIIB
Australia
Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program
Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%
$EBS$SABS